News from 89bio A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 25, 2019, 07:55 ET 89bio Announces Dosing of First Patients in NASH Study and Issuance of Composition of Matter Patent

89bio, Inc. (89bio or the company), a clinical-stage biopharmaceutical company, has initiated dosing in its proof of concept Phase 1b/2a clinical...


Aug 08, 2019, 07:53 ET 89bio Initiates Phase 1b/2a Proof of Concept Clinical Trial of Investigational Therapy BIO89-100 for the Treatment of NASH

89Bio Ltd. (89bio), a clinical-stage biopharmaceutical company, today announced that the first patients have been screened in its proof of concept...


May 22, 2019, 07:55 ET 89bio Reports Positive Top-line Data from Phase 1 Single-Ascending Dose Clinical Trial of BIO89-100, an Investigational Medicine for NASH

89bio LTD, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, today...


Apr 11, 2019, 20:00 ET 89bio Announces Preclinical Data That Demonstrate Potential Utility of BIO89-100 for Treatment of NASH

89bio LTD, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, today...


Mar 28, 2019, 07:53 ET 89bio Announces Late-Breaking Presentation at the EASL International Liver Congress™

89bio LTD, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, today...


Jan 03, 2019, 07:53 ET 89bio Appoints Hank Mansbach, M.D., as Chief Medical Officer

89bio, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, today...


Oct 25, 2018, 07:53 ET 89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing

89Bio, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, today...